CU Programme of Idarucizumab for Japanese Patients
Status:
Completed
Trial end date:
2016-09-16
Target enrollment:
Participant gender:
Summary
The objective is to collect the safety data of idarucizumab for patients treated with
dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of
uncontrolled or life-threatening bleeding or when emergency surgery or urgent procedures are
required.